The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions.

作者：Alistair R.D. McLean, Sumayyah Rashan, Lien Tran, Lorenzo Arena, AbdulAzeez Lawal, Brittany Maguire, Sandra Adele, Emilia Antonio, Matthew Brack, Fiona Caldwell, Verena I. Carrara, Reema Charles, Barbara Wanjiru Citarella, Terrence Epie, Vitalis Fambombi Feteh, Kalynn Kennon, Gerald Jamberi Makuka, Roland Cheofor Ngu, Amen-Patrick Nwosu, Sopuruchukwu Obiesie, Chinwe Ogbonnaa-Njoku, Parvesh Paul, Caitlin Richmond, Sauman Singh-Phulgenda, Samantha Strudwick, Carina S.B. Tyrrell, Kasia Stepniewska, Nathalie Strub‐Wourgaft, Nicholas J. White, Philippe J. Guérin · 发表于：Wellcome Open Research · 年份：2022 · DOI：10.12688/wellcomeopenres.17284.1 · 被引用次数：9 · 研究领域：Health Systems, Economic Evaluations, Quality of Life、Health and Medical Research Impacts、Pharmaceutical Practices and Patient Outcomes

Background: Many available medicines have been evaluated as potential repurposed treatments for coronavirus disease 2019 (COVID-19). We summarise the registered study landscape for 32 priority pharmacological treatments identified following consultation with external experts of the COVID-19 Clinical Research Coalition. Methods: All eligible trial registry records identified by systematic searches of the World Health Organisation International Clinical Trials Registry Platform as of 26 th May 2021 were reviewed and extracted. A descriptive summary of study characteristics was performed. Results: We identified 1,314 registered studies that included at least one of the 32 priority pharmacological interventions. The majority (1,043, 79%) were randomised controlled trials (RCTs). The sample size of the RCTs identified was typically small (median (25 th , 75 th percentile) sample size = 140 patients (70, 383)), i.e. individually powered only to show very large effects. The most extensively evaluated medicine was hydroxychloroquine (418 registered studies). Other widely studied interventions were convalescent plasma (n=208), ritonavir (n=189) usually combined with lopinavir (n=181), and azithromycin (n=147). Very few RCTs planned to recruit participants in low-income countries (n=14; 1.3%). A minority of studies (348, 26%) indicated a willingness to share individual participant data. The living systematic review data are available at https://iddo.cognitive.city ...